Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.53 USD
−60.66 M USD
1.88 M USD
22.19 M
About Insight Molecular Diagnostics Inc.
Sector
Industry
CEO
Joshua Riggs
Website
Headquarters
Nashville
Founded
2009
FIGI
BBG008P5VFV1
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Nashville, TN.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMDX is 2.86 USD — it has increased by 1.06% in the past 24 hours. Watch Insight Molecular Diagnostics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Insight Molecular Diagnostics Inc. stocks are traded under the ticker IMDX.
IMDX stock has fallen by −0.35% compared to the previous week, the month change is a −5.92% fall, over the last year Insight Molecular Diagnostics Inc. has showed a −11.18% decrease.
We've gathered analysts' opinions on Insight Molecular Diagnostics Inc. future price: according to them, IMDX price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch IMDX chart and read a more detailed Insight Molecular Diagnostics Inc. stock forecast: see what analysts think of Insight Molecular Diagnostics Inc. and suggest that you do with its stocks.
IMDX reached its all-time high on Jan 5, 2016 with the price of 4,096.00 USD, and its all-time low was 1.92 USD and was reached on Jan 22, 2025. View more price dynamics on IMDX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMDX stock is 3.54% volatile and has beta coefficient of −0.25. Track Insight Molecular Diagnostics Inc. stock price on the chart and check out the list of the most volatile stocks — is Insight Molecular Diagnostics Inc. there?
Today Insight Molecular Diagnostics Inc. has the market capitalization of 81.79 M, it has decreased by −1.05% over the last week.
Yes, you can track Insight Molecular Diagnostics Inc. financials in yearly and quarterly reports right on TradingView.
Insight Molecular Diagnostics Inc. is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
IMDX earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.24 USD resulting in a 20.73% surprise. The estimated earnings for the next quarter are −0.23 USD per share. See more details about Insight Molecular Diagnostics Inc. earnings.
Insight Molecular Diagnostics Inc. revenue for the last quarter amounts to 2.14 M USD, despite the estimated figure of 127.50 K USD. In the next quarter, revenue is expected to reach 291.95 K USD.
IMDX net income for the last quarter is −6.67 M USD, while the quarter before that showed −33.51 M USD of net income which accounts for 80.09% change. Track more Insight Molecular Diagnostics Inc. financial stats to get the full picture.
No, IMDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 19, 2025, the company has 49 employees. See our rating of the largest employees — is Insight Molecular Diagnostics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insight Molecular Diagnostics Inc. EBITDA is −21.66 M USD, and current EBITDA margin is −1.15 K%. See more stats in Insight Molecular Diagnostics Inc. financial statements.
Like other stocks, IMDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insight Molecular Diagnostics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Insight Molecular Diagnostics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Insight Molecular Diagnostics Inc. stock shows the sell signal. See more of Insight Molecular Diagnostics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.